Intracellular delivery of messenger RNA (mRNA)-based cancer vaccines have shown great
potential to activate antitumor immune response for cancer prevention and therapy. In vivo …

Intracellular delivery of messenger RNA (mRNA)-based cancer vaccine has shown great
potential to elicit antitumor immunity. To achieve robust antitumor efficacy, mRNA encoding …

Messenger RNA (mRNA)-based cancer vaccine has become a popular approach for
developing personalized and effective antitumor immunotherapy. To achieve robust …

The success of lipid nanoparticles (LNPs) in treating COVID-19 promotes further research of
mRNA vaccines for cancer vaccination. Aiming at overcoming the constraints of currently …

mRNA vaccines have evolved as promising cancer therapies. These vaccines can encode
tumor-allied antigens, thus enabling personalized treatment approaches. They can also …

The targeted delivery of messenger RNA (mRNA) to desired organs remains a great
challenge for in vivo applications of mRNA technology. For mRNA vaccines, the targeted …

During the past 2 years, messenger RNA (mRNA) nanovaccine has shown its remarkable
antiviral efficacy, rapid manufacture, and good safety profile for preventing coronavirus …

For efficient cancer vaccines, the antitumor function largely relies on cytotoxic T cells, whose
activation can be effectively induced via antigen-encoding mRNA, making mRNA-based …

With its unique properties and potential applications, nanoparticle-based delivery platforms
for messenger RNA (mRNA) vaccines have gained significant attention in recent years …

The delivery of lipid nanoparticle (LNP)-based mRNA therapeutics has captured the
attention of the vaccine research community as an innovative and versatile tool for treating a …